Nomura: maintains Xtep International (01368) "buy" rating, target price lowered to 7.5 Hong Kong dollars.
The inventory turnover of Xtep International is still maintained at a healthy level of 4 months.
Nomura has released a research report stating that the target price of XTEP INT'L (01368) has been raised by 5.6% to 7.5 Hong Kong dollars from 7.1 Hong Kong dollars, maintaining a "buy" rating.
The report states that Xtep is expected to recover sales momentum in the fourth quarter of 2024. The company has announced its operational data for the fourth quarter of 2024: Xtep brand is showing signs of recovery, with sales in the fourth quarter recording high single-digit growth year-on-year, faster than the mid-single-digit growth in the third quarter; therefore, Xtep's full-year sales in 2024 are expected to achieve high single-digit growth year-on-year. Inventory turnover remains at a healthy level of 4 months.
However, the report points out that Xtep expanded retail discounts to 25-30% in the fourth quarter, indicating the company's efforts to boost sales in the past quarter. Meanwhile, sales momentum for its brand Saucony remained robust in the fourth quarter, with a year-on-year increase of around 50%, slightly slower than the over 50% growth in the third quarter; for the full year of 2024, Saucony's sales are expected to increase by over 60%, becoming a strong emerging brand.
Related Articles

FUSEN PHARM(01652): "Compound Potassium Dihydrogen Phosphate Injection" approved for market.

Tech Inc. (06082) has attracted a strong demand for its IPO, with oversubscribed share offerings exceeding HKD 38 billion, oversubscribed by over 1500 times.

ALPHAMAB-B(09966): The IND application for a Phase II clinical trial of JSKN033 has been formally accepted by the CDE.
FUSEN PHARM(01652): "Compound Potassium Dihydrogen Phosphate Injection" approved for market.

Tech Inc. (06082) has attracted a strong demand for its IPO, with oversubscribed share offerings exceeding HKD 38 billion, oversubscribed by over 1500 times.

ALPHAMAB-B(09966): The IND application for a Phase II clinical trial of JSKN033 has been formally accepted by the CDE.

RECOMMEND

Not Just “Power Shortages,” Delays Will Become The Key Theme For U.S. Data Centers In 2026
26/12/2025

Hang Seng Index Rises 33% This Year, Best Five‑Year Performance; Multiple Institutions Forecast Breakthrough Above 30,000 Next Year
26/12/2025

Gold Rally Has Further To Run, JPMorgan Bullish: Prices Could Reach USD 5,055 By Year‑End 2026
26/12/2025


